Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Certara, Inc. stock logo
CERT
Certara
$10.33
+2.4%		$8.73
$4.45
▼
$12.94
$1.54B1.422.84 million shs2.06 million shs
Evolent Health, Inc stock logo
EVH
Evolent Health
$4.79
-2.1%		$4.21
$2.10
▼
$7.91
$552.86M1.022.12 million shs1.23 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.54
-2.2%		$3.44
$1.77
▼
$4.05
$1.24B1.69947,300 shs1.14 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$23.80
+5.3%		$24.06
$10.94
▼
$33.78
$1.67B1.622.62 million shs1.14 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Certara, Inc. stock logo
CERT
Certara
-0.88%+4.45%+14.27%+34.35%-20.68%
Evolent Health, Inc stock logo
EVH
Evolent Health
+1.64%+0.99%+29.30%+17.13%-39.58%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
+1.40%+3.13%+5.23%+22.30%-3.98%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-5.44%-11.30%-26.38%+50.97%+8.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Certara, Inc. stock logo
CERT
Certara
$10.33
+2.4%		$8.73
$4.45
▼
$12.94
$1.54B1.422.84 million shs2.06 million shs
Evolent Health, Inc stock logo
EVH
Evolent Health
$4.79
-2.1%		$4.21
$2.10
▼
$7.91
$552.86M1.022.12 million shs1.23 million shs
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$3.54
-2.2%		$3.44
$1.77
▼
$4.05
$1.24B1.69947,300 shs1.14 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$23.80
+5.3%		$24.06
$10.94
▼
$33.78
$1.67B1.622.62 million shs1.14 million shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Certara, Inc. stock logo
CERT
Certara
-0.88%+4.45%+14.27%+34.35%-20.68%
Evolent Health, Inc stock logo
EVH
Evolent Health
+1.64%+0.99%+29.30%+17.13%-39.58%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
+1.40%+3.13%+5.23%+22.30%-3.98%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-5.44%-11.30%-26.38%+50.97%+8.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Certara, Inc. stock logo
CERT
Certara
2.42
Hold$9.18-11.12% Downside
Evolent Health, Inc stock logo
EVH
Evolent Health
2.63
Moderate Buy$5.9624.65% Upside
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
2.08
Hold$4.2319.41% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.63
Moderate Buy$25.838.54% Upside

Current Analyst Ratings Breakdown

Latest EVH, SDGR, CERT, and GDRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/20/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$19.00 ➝ $21.00
10/16/2026
Evolent Health, Inc stock logo
EVH
Evolent Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
10/16/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$20.00 ➝ $32.00
10/16/2026
Certara, Inc. stock logo
CERT
Certara
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$9.00 ➝ $12.00
10/13/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$20.00 ➝ $31.00
10/13/2026
Certara, Inc. stock logo
CERT
Certara
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$9.00 ➝ $11.00
10/12/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$24.00 ➝ $30.00
10/8/2026
Certara, Inc. stock logo
CERT
Certara
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D) ➝ Sell (D-)
10/7/2026
Certara, Inc. stock logo
CERT
Certara
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$7.50 ➝ $9.00
10/5/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
10/2/2026
Evolent Health, Inc stock logo
EVH
Evolent Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Certara, Inc. stock logo
CERT
Certara
$418.84M3.76$0.77 per share13.34$6.67 per share1.55
Evolent Health, Inc stock logo
EVH
Evolent Health
$1.88B0.29$4.60 per share1.04$3.53 per share1.36
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$796.85M1.52$0.39 per share9.05$1.81 per share1.96
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$255.87M6.87N/AN/A$4.94 per share4.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Certara, Inc. stock logo
CERT
Certara
-$1.60M-$0.45N/A36.89N/A-16.75%3.86%2.65%11/5/2026 (Estimated)
Evolent Health, Inc stock logo
EVH
Evolent Health
-$534.51M-$4.57N/AN/AN/A-24.08%-4.27%-1.06%11/5/2026 (Estimated)
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$30.44M$0.0488.5217.701.802.07%7.22%2.53%11/3/2026 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$103.26M-$0.74N/AN/AN/A-20.98%-16.37%-8.19%11/4/2026 (Estimated)

Latest EVH, SDGR, CERT, and GDRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Certara, Inc. stock logo
CERT
Certara
$0.0866N/AN/AN/A$91.93 millionN/A
11/5/2026Q3 2026
Evolent Health, Inc stock logo
EVH
Evolent Health
$0.06N/AN/AN/A$727.06 millionN/A
11/4/2026Q3 2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.6665N/AN/AN/A$47.67 millionN/A
11/3/2026Q3 2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.0777N/AN/AN/A$202.07 millionN/A
8/6/2026Q2 2026
Evolent Health, Inc stock logo
EVH
Evolent Health
-$0.0104$0.02+$0.0304-$0.25$597.70 million$484.50 million
8/5/2026Q2 2026
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
$0.0797$0.08+$0.0003$0.02$193.23 million$200.41 million
8/5/2026Q2 2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.4145$0.08+$0.4945$0.08$47.19 million$58.89 million
8/4/2026Q2 2026
Certara, Inc. stock logo
CERT
Certara
$0.0893$0.08-$0.0093-$0.36$98.09 million$93.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Certara, Inc. stock logo
CERT
Certara
N/AN/AN/AN/AN/A
Evolent Health, Inc stock logo
EVH
Evolent Health
N/AN/AN/AN/AN/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Certara, Inc. stock logo
CERT
Certara
0.30
2.55
2.55
Evolent Health, Inc stock logo
EVH
Evolent Health
2.52
1.24
1.24
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
0.74
1.38
1.38
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
2.71
2.71

Institutional Ownership

CompanyInstitutional Ownership
Certara, Inc. stock logo
CERT
Certara
73.96%
Evolent Health, Inc stock logo
EVH
Evolent Health
N/A
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
63.77%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%

Insider Ownership

CompanyInsider Ownership
Certara, Inc. stock logo
CERT
Certara
1.08%
Evolent Health, Inc stock logo
EVH
Evolent Health
1.48%
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
5.87%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
10.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Certara, Inc. stock logo
CERT
Certara
1,576152.54 million150.89 millionOptionable
Evolent Health, Inc stock logo
EVH
Evolent Health
4,200113.06 million111.39 millionOptionable
GoodRx Holdings, Inc. stock logo
GDRX
GoodRx
697342.57 million322.47 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
85073.82 million66.37 millionOptionable

Recent News About These Companies

Schrödinger consensus price target increased by 16.67% to $25.50
October 23 at 9:31 AM  |  msn.comhttps://www.msn.com/en-us/news/other/schr%C3%B6dinger-consensus-price-target-increased-by-1667-to-2550/ar-AA2fUFgY
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
October 21 at 12:53 PM  |  marketscreener.comM
TD Cowen raises target for Schrodinger stock to USD 31.00
October 21 at 12:53 PM  |  ad-hoc-news.deA
UBS Adjusts Schrodinger Price Target to $21 From $19, Maintains Neutral Rating
October 21 at 7:42 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ubs-adjusts-schrodinger-price-target-140908690.html
Schrodinger (NASDAQ:SDGR) Stock Price Expected to Rise, UBS Group Analyst Says
October 20 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-schrodinger-nasdaq-sdgr-stock-price-expected-to-rise-ubs-group-analyst-says-2026-10-20/
Schrodinger stock fell 11.30 percent on October 16, 2026, 33.10 percent below high
October 18, 2026  |  ad-hoc-news.deA
Schrodinger (NASDAQ:SDGR) Stock Price Down 7.4% - Here's What Happened
October 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-stock-price-down-74-heres-what-happened-2026-10-16/
TD Cowen lifts target for Schrödinger stock to USD 31.00
October 15, 2026  |  ad-hoc-news.deA
What kind of company is Schrödinger (SDGR)? A 'dual-track' platform company that sells software for drug design while also earning revenue from drug discovery
October 15, 2026  |  note.comN
Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
October 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261014415587/en/schr%c3%b6dinger-research-published-in-nature-reveals-new-insights-into-lithium-ion-battery-chemistry/
Schrodinger, Inc. (NASDAQ:SDGR) Stock Has Average Price Target of $23.50
October 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117599
Schrodinger, Inc. (NASDAQ:SDGR) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
October 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-schrodinger-inc-nasdaq-sdgr-stock-now-rated-moderate-buy-by-wall-street-brokerages-2026-10-14/
Schrödinger (SDGR) Stock Fair Value Edges Higher As Analyst Views Split On AI Growth
October 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/schr-dinger-sdgr-stock-fair-021328504.html
[SDGR] ACV up 27%, software revenue down 10%. What happened to Schrödinger?
October 12, 2026  |  note.comN
Schrodinger (NASDAQ:SDGR) and Claritev (NYSE:CTEV) Head to Head Review
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110096
[SDGR] BMS to implement drug discovery AI 'Bunsen' on a large scale. How should we interpret this step toward drug discovery infrastructure? | Chapter 14
October 10, 2026  |  note.comN
Schrodinger Inc (SDGR) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 72/100
October 9, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9118182/schrodinger-inc-sdgr-stock-up-34-but-gf-value-says-overvalued-gf-score-72100
Generating Revenue Before Drug Approval: Schrödinger's AI Drug Discovery Software
October 9, 2026  |  note.comN
Schrodinger (NASDAQ:SDGR) Stock Price Up 6.1% - What's Next?
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-stock-price-up-61-whats-next-2026-10-09/
Schrödinger stock falls 5.57 percent on October 7, 2026
October 8, 2026  |  ad-hoc-news.deA
Schrodinger (NASDAQ:SDGR) Upgraded to Strong-Buy at Zacks Research
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-schrodinger-nasdaq-sdgr-upgraded-to-strong-buy-at-zacks-research-2026-10-07/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Close-up of computer chips on a circuit board with a candlestick stock chart overlay in the background.
AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
By Nathan Reiff | September 30, 2026
Conceptual image of an AMD processor chip with a miniature illuminated city rendered on its surface.
Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
By Nathan Reiff | October 1, 2026
Illustration of a quantum computer's golden cryostat chandelier with cables, set in a futuristic laboratory environment.
The Pentagon's $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
By Nathan Reiff | October 13, 2026
A pie baked with one-dollar and five-dollar bills inside, with one slice cut out, symbolizing profit sharing.
3 Stocks Delivering Bigger Dividends Despite Market Uncertainty
By Leo Miller | October 17, 2026
A large oil tanker ship sails across open ocean water during a colorful sunset with distant mountains.
Okeanis Riding Record Profits as Uncertainty Grows
By Peter Frank | October 16, 2026
Certara stock logo

Certara NASDAQ:CERT

$10.33 +0.24 (+2.38%)
Closing price 04:00 PM Eastern
Extended Trading
$10.61 +0.28 (+2.70%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Evolent Health stock logo

Evolent Health NYSE:EVH

$4.78 -0.11 (-2.15%)
Closing price 03:59 PM Eastern
Extended Trading
$4.80 +0.01 (+0.21%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

GoodRx stock logo

GoodRx NASDAQ:GDRX

$3.54 -0.08 (-2.21%)
Closing price 04:00 PM Eastern
Extended Trading
$3.53 -0.01 (-0.40%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$23.80 +1.20 (+5.31%)
Closing price 04:00 PM Eastern
Extended Trading
$23.97 +0.17 (+0.71%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas